Xtalks Webinars
@Xtalks
Followers
26K
Following
4K
Media
5K
Statuses
18K
Provides insight on Life Science issues (#Pharma, #Biotech, #MedicalDevice) via breaking news & interactive webinars with industry experts
Online
Joined April 2010
Our World Diabetes Day 2025 breakdown spotlights new WHO guidance, clinical data for type 1 diabetes, evolving insulin delivery tech and emerging tools for wound care. Read more by @soumya2390 at https://t.co/LmWGYrKymr.
#WorldDiabetesDay2025 #DiabetesCare #Type1Diabetes
xtalks.com
Learn how early-stage research, new technologies and global guidance are shaping care on World Diabetes Day 2025.
0
0
0
According to https://t.co/QTnp7TpMNc data, US spending on prescription drug TV ads hit $1.25 billion in Q3 2025, with October alone shattering records at $307 million. From immunology and obesity drugs to CNS therapies, pharma’s biggest brands are still betting big on the power
0
0
0
🔁 Friday Rewind with Xtalks This week on Xtalks’ tape rewind: clinical research, ad spend swings, gene therapy bets and pharma drama. 📺 Pharma TV Ad Spend Surges in Q3 2025 Scan the numbers: https://t.co/CieArGoxTT 👁️ RWD + Decentralized Designs in Ophthalmology Trials
xtalks.com
According to iSpot.tv data, US spending on prescription drug TV ads hit $1.25 billion in Q3 2025, with October shattering records.
0
0
0
Vote and see results in our latest Xtalks Life Science Poll: What technology do you think will transform clinical trials by 2030 the most, AI, decentralized trial platforms, wearables or real-world data (RWD) integration? Vote and see results here: https://t.co/hwYAKPoWBm
0
0
0
Explore cutting-edge strategies for tackling peptide degradation with Elizabeth Denton, PhD and Caroline Proulx, PhD from Biotage®. They will reveal how replacing the alpha carbon to create azapeptides alters conformation and facilitates the creation of large libraries,
0
0
0
Eli Lilly has partnered with Tan France from Netflix's Queer Eye on its new “Changing the Thread Collection” Zepbound campaign that weaves together fashion, storytelling and science to challenge obesity stigma. Read more at https://t.co/Ealgr7L1yl.
#EliLilly #Zepbound #TanFrance
0
0
0
In this episode, Rectify Pharma CMO Dr. Pol Boudes discusses how innovation in hepatobiliary diseases is gaining new momentum, driven by novel approaches to correcting protein misfolding at its source. Listen now at https://t.co/dG3ngHBxPG 🎙️
0
0
0
Recent weeks brought more workforce shifts in medtech, with Olympus, Abbott, Medtronic and Philips all announcing job cuts. See who’s been added to our Medtech Layoffs 2025 roundup by @soumya2390 at https://t.co/zTLZEvh300.
#MedTechLayoffs #MedicalDevices #MedTechNews
xtalks.com
Read our medtech layoffs 2025 roundup to stay informed on industry updates and learn how strategic realignment can drive cost control.
0
0
0
New Phase III data spotlight Merck’s enlicitide decanoate’s once-daily oral approach to LDL-C reduction. Our article unpacks key lipid results, and what comes next for this investigational PCSK9 inhibitor at https://t.co/MKq6dHEoyX by @soumya2390. #Merck #Cholesterol
0
0
0
Discover how to navigate the complexities of eCOA and Digital Health Technologies (DHTs) for your cardiometabolic trials with Clinical ink. Join experts Nicholas Alp, MD, PhD, FACC, Steve Polyak, PhD, Bill Barrasso, MBA, Jennifer Guild, MBA, PMP, and Jessica Ryter, MBA as they
0
0
0
Navigate the high-stakes impact of Medicare's Year 2 drug negotiation program with experts Mike Ciarametaro, Neil Lund, Milena Sullivan, and Taylor Schwartz from Avalere Health. In this on-demand webinar, they break down how Maximum Fair Price (MFP) determinations are
0
0
0
For millions, dry eye disease feels like having an eyelash in your eye every hour of every day, with no relief. Elizabeth Jeffords, CEO of Iolyx Therapeutics, shares how understanding patient experience and autoimmune drivers is reshaping treatment approaches for this overlooked
0
0
0
Uncover the emerging trends driving the future of cancer care with Dr. Jozsef Palatka, MD, Dr. Rob Berg, MD, PhD, and Marek Rombel from Syneos Health®. Learn which cutting-edge treatment modalities, from evolving immuno-oncology to next-wave Antibody-Drug Conjugates (ADCs), are
0
0
0
Join Diandra Donald, Jessica Bell, and Catherine Tyner from AG Mednet as they discuss how to build a practical framework for successful imaging strategies in modern clinical trials. Discover validated strategies for identifying blind spots, anticipating common pitfalls, and
0
0
0
Evommune joins the lineup. Check out the new player in chronic inflammation and explore the latest Pharma & Biotech M&A Roundup on Xtalks for 2025’s biggest deals and trends by @soumya2390 at https://t.co/YVoRXG7HxL.
#PharmaNews #BiotechDeals #ChronicInflammation #LifeSciences
xtalks.com
Pharma and biotech IPOs in 2025 offer novel investment opportunities. Here are 10 pharma and biotech companies that went public in 2025.
0
0
0
Hospitals and health systems across the US and Canada are announcing new layoffs. Our Healthcare Layoffs 2025 Roundup blog tracks the latest updates, from Sentara to Kaiser. Read more by @soumya2390 at https://t.co/nCtrubp8Sf.
#HealthcareLayoffs #HospitalNews #HealthSystems
1
0
0
Pfizer has lost its court bid to block Novo Nordisk’s counteroffer for the obesity drug biotech. Read more at https://t.co/JYQIhJdTrb.
#Pfizer #NovoNordisk #Metsera #ObesityDrugs #PharmaLawsuit
xtalks.com
Pfizer has lost its court bid to block Novo Nordisk’s counteroffer for US-based obesity drug biotech Metsera.
0
0
0
Palo Alto, California, biotech Evommune is set to bring fresh momentum to chronic inflammation research. The $150M IPO will advance oral and injectable therapies that target diseases like urticaria and dermatitis. Learn more at https://t.co/kysTvCvGTr by @soumya2390.
xtalks.com
Proceeds from the Evommune IPO will fund clinical programs, expand discovery-stage research and support future regulatory milestones.
0
0
0
With facilities and equipment designed for fast adaptability, learn how FUJIFILM Biotechnologies can scale manufacturing operations in response to both product and market requirements, whether by increasing capacity or shifting production strategies. Read more at
0
0
0